Loading...
The integration of taxanes into adjuvant chemotherapy regimens has incrementally improved the outcomes of patients with early-stage breast cancer (J Clin Oncol 2008; 26:44). Recently, researchers have focused on identifying the optimal taxane, schedule, and patient population to derive the greatest benefit from this approach (JW Oncol Hematol Oct 10 2007). Now, investigators provide more information about the nuances of concurrently integrating docetaxel and doxorubicin into adjuvant-therapy regimens. Perhaps more important, they also analyze tumor gene expression in light of the view that outcomes are influenced by more than just the classic prognostic markers such as tumor size and number of axillary lymph nodes involved. The North Americ…